SNDX

Syndax Pharmaceuticals Inc

• PUBT·4d ago

  Syndax CEO Michael Metzger disposes of common shares worth $784,274.98

• Simply Wall St·5d ago

  Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next

• Simply Wall St·07/04 20:26

  Syndax Pharmaceuticals (SNDX) Reports Strong Revuforj Data, Is The Upside Already Priced In?

• PUBT·07/01 20:01

  Syndax grants stock option inducement awards for 250,700 shares to eight new employees

• Reuters·07/01 20:01

  SYNDAX PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

• Simply Wall St·06/29 03:22

  Does Syndax Pharmaceuticals’ (SNDX) Russell Value Index Exit Quietly Recast Its Liquidity And Risk Narrative?

• Seeking Alpha·06/26 13:22

  Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)

• Simply Wall St·06/22 08:27

  Syndax Pharmaceuticals (SNDX) Stock Could Be 51.9% Undervalued After SAVE Trial Data

• Simply Wall St·06/20 22:24

  Is Strong SAVE Trial Data Altering The Investment Case For Syndax Pharmaceuticals (SNDX)?

• Simply Wall St·06/14 17:13

  Syndax Pharmaceuticals (SNDX) Stock Valuation After Positive SAVE Trial Data In High-Risk Leukemia

• Simply Wall St·06/13 12:22

  Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral SAVE Trial Remission Data Reported

• Dow Jones·06/12 12:26

  Syndax Pharmaceuticals Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

• Benzinga·06/12 12:16

  HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target

• TipRanks·06/12 11:39

  Syndax Pharmaceuticals (SNDX) Gets a Buy from Guggenheim

• TipRanks·06/12 11:11

  Syndax price target lowered to $31 from $34 at Guggenheim